671 results about "Osteocyte" patented technology

The invention belongs to the technical field of hydrogel, and relates to piezoelectric / conductive integrated hydrogel for jaw defect repair, which is prepared from methylacryloyl protein, zwitterionic monomer and titanate piezoelectric particles through ultraviolet crosslinking under the action of a crosslinking agent and a photoinitiator, the hydrogel comprises, by mass, 1.0%-10% of methacrylated protein, 1.0%-10% of zwitterionic monomers, 1.0%-10% of titanate piezoelectric particles and 0.1%-5% of an initiator, and the volume fraction of an accelerant is 0.05%-1.0%. The hydrogel disclosed by the invention has excellent mechanical strength and certain flexibility, can realize piezoelectric and conductive functions of the hydrogel, can effectively promote proliferation, differentiation and mineralization of bone cells under the action of an electric field, accelerates bone tissue repair, and has a more remarkable bone regeneration effect compared with a non-electrical stimulation material in the prior art.

The invention relates to the technical field of biological medicines, and provides application of an ADRM1 inhibitor in preparation of a medicine for treating osteoporosis. Through the scheme of the invention, the ADRM1 affects bone metabolism, bone tissue morphological structure and osteoporosis progress, and can provide a new drug target for clinical prevention and treatment of osteoporosis. The ADRM1 inhibitor is applied to preparation of the osteoporosis medicine, and bone mass loss can be obviously reduced by down-regulating ADRM1 expression or inhibiting ADRM1 activity and inhibiting differentiation and functions of osteoclasts, so that the effect of treating osteoporosis is achieved.

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The invention provides an application of bifidobacterium animalis subsp. Lactis CP-9 in preparation of a product for promoting bone growth and development or improving bone health. Long-term research and a large number of experiments show that the bifidobacterium animalis subsp. Lactis CP-9 can improve the bone volume fraction, the bone trabecula thickness, the bone density and the bone volume of an organism, and can also effectively improve the growth hormone level and the insulin-like growth factor 1 level, so that bone growth and development are promoted. Meanwhile, the bifidobacterium animalis subsp. Lactis CP-9 can effectively improve the N-terminal propeptide level, osteocalcin level, bone morphogenetic protein level and osteoprotectin level of I-type procollagen in a body, and remarkably reduce the amino-terminal peptide level of the I-type collagen and the ligand level of nuclear factor kappa B receptor activating factor, so that osteoblast differentiation is promoted, osteoclast differentiation is inhibited, and osteoclast differentiation is inhibited. Furthermore, bone formation is promoted, bone resorption is inhibited, bone metabolism is improved, and finally the effect of improving bone health is achieved.

Provided are compositions comprising a HKUOT-S2 protein, at least one peptide according to at least one of SEQ ID NO: 81-97, or a protein comprising an amino acid sequence according to at least one of SEQ ID NO: 81-97. Methods of osteogenesis are provided, including, for example, methods of enhancing bone repair, modulating polarization of macrophages with proinflammatory and anti-inflammatory activity and bone resorption of osteoclasts, and methods of treating inflammatory diseases, spinal cord injury, liver and kidney diseases, cardiovascular diseases, diabetes, post-menopausal syndrome, infertility, or hematopoietic diseases, or enhancing wound healing.

The invention discloses a preparation method and application of high-strength, high-inorganic-ratio and degradable organic-inorganic composite hydrogel, and belongs to the technical field of biomedical tissue engineering. The hydrogel is prepared from the following components in percentage by weight: 30 to 70 percent of calcium phosphate nano-cluster and 30 to 70 percent of sodium alginate. The organic-inorganic composite hydrogel is beneficial to proliferation and mineralization of bone cells, and more ideal bone guidance is realized. Experimental results prove that the material has good cytocompatibility, can quickly promote rat skull defect repair (8 mm limit bone injury repair time is shortened to 4 weeks), and has a more remarkable healing effect compared with a contrast autogenous bone graft material with an optimal clinical repair effect. The high-strength organic-inorganic composite hydrogel prepared by the invention is of a single-network structure, shows good mechanical properties, also has excellent degradability matched with tissues, and is beneficial to hard tissue repair.

The invention belongs to the field of biological medicines, and discloses an application of Akkermansia muciniphila or an extracellular vesicle of the Akkermansia muciniphila in preparation of a medicine for alleviating the ischemic necrosis of the alcoholic femoral head. Based on the pathogenesis characteristics of the AIONFH, the Akk bacteria and the extracellular vesicles thereof are used for treating the AIONFH for the first time, the molecular mechanism of the Akk bacteria and the extracellular vesicles thereof for regulating and controlling the intestinal tract-skeleton axis function, inhibiting bone cell apoptosis and improving the bone trabecula microstructure is deeply researched, the anti-pressure ability of bone tissue is improved, and the research blank in the field is filled. Compared with a traditional treatment method, the osteonecrosis pathological change is improved through a single way, and a novel multi-target treatment strategy is provided from multiple aspects of regulating inflammatory response, recovering bone metabolism balance, promoting intraosseous blood supply and the like.

Orthopedic implants, particularly interbody spacers, have a combination of correct pore size and stiffness / flexibility. When the implants have the proper pore size and stiffness, osteocytes are able to properly bridge the pores of the implant and then experience a proper compressive load to stimulate the bone cells to form bone within the pores. An implant includes a body formed of an osteoconductive material and having a stiffness of between 400 megapascals (MPa) and 1,200 MPa. Additionally, the body includes a plurality of pores having an average size of between 150 microns and 600 microns. The pores permit the growth of bone therein. The body is formed of packs of coils which may be formed using an additive manufacturing process and using traditional orthopedic implant materials such as titanium and titanium alloys while still achieving desired stiffness and pore sizes of the implants.

The invention discloses a method and a device for acquiring parameters of an internal fracture fixation system, and relates to the technical field of medical data processing. Constructing a digital model of the skeleton and the surrounding soft tissue based on the three-dimensional scanning image by utilizing a biomechanical principle; using a machine learning algorithm to train the historical case data, and generating a preliminary internal fixed parameter prediction model; applying the preliminary parameters to a digital model for simulation verification, and optimizing the internal fixed parameters to an optimal combination; performing personalized adjustment on the simulation result according to individual differences of patients and experience of clinical doctors; the state of the internal fixation system is monitored in real time in the operation process, and parameter fine adjustment is conducted according to feedback; the fracture healing condition is regularly evaluated after the operation, and the internal fixation parameters are adjusted according to the evaluation result. Through personalized and precise internal fixation parameter setting, a good mechanical repair environment is created for a fracture part, bone cell proliferation and ordered growth of callus are promoted, and the healing time is effectively shortened.

A method for constructing a microfluidic bone organoid-on-chip can continuously observe the impacts of different external factors on a bone tissue structure based on the “ternary regulation theory” of bone angiogenesis-bone resorption-osteogenesis coupling. The method includes: (1) building a visual three-dimensional cell cultivation platform to continuously observe impacts of different external factors on a ternary regulation theory based on angiogenesis of osteoclast precursors, osteoblasts and osteoclasts, such that a user is allowed to directly observe interactions among various kinds of cells; (2) designing microfluidic channels in a chip to allow a reagent involved to present a concentration gradient distribution in the chip; and (3) adding three bioinks including osteoblasts, osteoclasts and vascular endothelial cells respectively, so as to reflect the three cell components individually, in pairs, and as a whole in the chip. An apparatus for constructing a microfluidic bone organoid-on-chip is further provided.

The invention discloses an artificial bone for promoting osteoporotic bone defect repair and a preparation method thereof, and belongs to the technical field of biomedical materials. The artificial bone disclosed by the invention is prepared by compounding the following components in percentage by weight: 89.65 to 89.85 weight percent of polylactic acid-glycolic acid copolymer, 9.85 to 10.15 weight percent of nano hydroxyapatite and 0.1 to 0.5 weight percent of zoledronic acid. In the artificial bone, the nano-hydroxyapatite and zoledronic acid are uniformly dispersed in the polylactic acid-glycolic acid copolymer, and the porous structure on the surface of the artificial bone is combined, so that osteoblasts can be attached to the surface of the artificial bone, and new bone tissues can grow in the artificial bone; phosphonate radicals of zoledronic acid can be chelated with nano-hydroxyapatite to generate stable chemical bonds, the stable chemical bonds are introduced into the polylactic acid-glycolic acid copolymer, effective loading of zoledronic acid can be achieved, and the effective loading of zoledronic acid can inhibit bone resorption increase caused by overactivation of osteoclasts and repair osteoporotic bone defects.

The invention discloses combined lactobacillus salivarius CCFM1327 capable of inhibiting foaming of macrophages and relieving periodontitis, and belongs to the technical field of microorganisms. According to the invention, the strain of combined lactobacillus salivarius CCFM1327 is obtained, and the combined lactobacillus salivarius has the effects of inhibiting foaming of macrophages and relieving periodontitis, which are specifically reflected in that the combined lactobacillus salivarius can inhibit foaming of RAW264.7 cells caused by ox-LDL; the growth of porphyromonas gingivalis can be effectively inhibited; the periodontal probing and diagnosing depth of the periodontitis rats can be obviously reduced; the number of pathogenic bacteria in the oral cavity of the periodontitis rat is reduced; the level of an inflammatory factor IL-17A in serum is reduced; alveolar bone loss of rats suffering from periodontitis is reduced; and the number of alveolar bone osteoclasts is reduced.

The invention discloses a medicine for treating osteoarthritis, and belongs to the field of medicine, the medicine comprises a reagent capable of stimulating chondrocyte development, and the medicine L-arginine can promote expression of chondrocyte anabolic factors and reduce expression of cartilage degradation markers, so that chondrocytes are protected to a certain extent; in addition, the medicine provided by the invention has an excellent cartilage repair function, can inhibit the progress of degenerative osteoarthritis, has good biocompatibility, and has no cytotoxicity to cartilage cells.

The invention discloses a calcium-containing antarctic krill oligopeptide nutritional composition for promoting bone cell growth and application thereof, and belongs to the technical field of functional foods.The calcium-containing antarctic krill oligopeptide nutritional composition is composed of antarctic krill oligopeptide and a calcium compound, and the mass ratio of the antarctic krill oligopeptide to the calcium compound is (0.5-5): 1; or the composition is composed of the euphausia superba oligopeptide, the calcium compound and the vitamin D, and the mass ratio of the euphausia superba oligopeptide to the calcium compound to the vitamin D is (0.5-5): 1: (2.5 * 10 <-5 >)-(15 * 10 <-5 >); the mass of the calcium compound is calculated according to the content of the calcium element in the antarctic krill oligopeptide; the antarctic krill oligopeptide is obtained by treating antarctic krill, antarctic krill powder or defatted antarctic krill powder by utilizing an enzymolysis method; the content of a peptide fragment with the molecular weight of less than 1000Da in the antarctic krill The raw materials of the nutritional composition are easy to obtain, the safety is high, and the nutritional composition can be used for preparing products with the effect of promoting bone cell growth.

The invention belongs to the field of medicines, and particularly relates to application of a new target NCSTN for regulating and controlling bone metabolism and an agonist of the new target NCSTN in preparation of a medicine for preventing or treating osteoporosis. The invention aims to provide a new target NCSTN for regulating and controlling bone metabolism and application of the new target NCSTN in promoting osteogenic activity, inhibiting osteoclast activity and treating osteoporosis. According to the invention, the mechanism of the NCSTN agonist for treating osteoporosis is found for the first time, and the NCSTN agonist has the effects of inhibiting osteoclast maturation and differentiation and promoting osteoblast bone formation function. The mechanism is greatly different from the previously reported mechanism of singly inhibiting bone resorption or singly promoting bone formation, and the osteoporosis treatment which simultaneously acts on bone resorption and bone formation can greatly reduce the adverse reaction of the body to the medicine.

The invention relates to the field of application of medicines for treating rheumatoid arthritis, and discloses an application method of targeted MTHFD2 in preparation of medicines for treating bone destruction of rheumatoid arthritis, (1) the level of MTHFD2 in knee joints of rheumatoid arthritis patients and mice is increased; (2) the expression of MTHFD2 is up-regulated in the process of differentiating osteoclast precursor cells from mice and humans into osteoclasts; (3) the MTHFD2 inhibitor can significantly inhibit differentiation of osteoclasts from mice and humans; (4) MTHFD2 gene silencing can inhibit differentiation of mouse-derived osteoclasts, MTHFD2 gene overexpression can promote differentiation of osteoclasts, and reliability of MTHFD2 as a therapeutic target is verified; and (5) the MTHFD2 inhibitor can improve the bone destruction of arthritis mice and increase the bone tissue density, which prompts that the targeted MTHFD2 is useful for the treatment or prevention of rheumatoid arthritis and other diseases.

The invention relates to an application of a CTHRC1 inhibitor in preparation of a medicine for preventing and / or treating arthritis. Specifically, the invention provides application of an inhibitor or an antagonist of a CTHRC1 gene or a protein thereof, the inhibitor or the antagonist is used for preparing a composition or a preparation, and the composition or the preparation is used for (a) preventing and / or treating arthritis-related diseases; and / or (b) inhibiting cartilage cell senescence.

The invention relates to the technical field of medicine, in particular to application of beta-hydroxybutyric acid in preparation of medicine for preventing and / or treating osteoporosis, the osteoporosis comprises postmenopausal osteoporosis and diabetic osteoporosis due to estrogen deficiency, the administration concentration of the beta-hydroxybutyric acid is 150mM, and the administration concentration of the beta-hydroxybutyric acid is 10mM. According to the application of the beta-hydroxybutyric acid in preparing the medicine for inhibiting osteoclast differentiation or osteoclast formation, the beta-hydroxybutyric acid inhibits osteoclast precursor cells from being differentiated into osteoclasts, and the administration concentration of the beta-hydroxybutyric acid is 10 mM; the invention proves that the beta-hydroxybutyric acid improves bone microstructures of OVX mice and db / db mice, inhibits osteoclast differentiation and reduces bone resorption, and provides a new target for prevention and treatment of osteoporosis.

The invention discloses a yak bone collagen peptide for improving osteoporosis and preparation and application thereof, and relates to the field of biological medicine, the yak bone collagen peptide comprises collagen peptide with the molecular weight of 500-2000 Daltons, contains a glycine-proline-hydroxyproline tripeptide core structure, can promote osteoblast differentiation and inhibit osteoclast activity, and can be used for treating osteoporosis. The amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine, and the amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine; and the amino acid is glycine, proline, hydroxyproline, serine, leucine and alanine. The yak bone collagen peptide has a unique glycine-proline-hydroxyproline tripeptide structure, the molecular weight is controlled within the range of 500-2000 Daltons, the structure can promote osteoblast differentiation and inhibit osteoclast activity at the same time, and the problem that a traditional osteoporosis treatment medicine is single in function is solved.

The invention discloses a method for inducing osteoblasts by using mesenchymal stem cells, and belongs to the technical field of biology. The method for inducing the osteoblasts comprises the step of adding brucella outer membrane protein into a conventional osteoblast induction culture medium to promote the dental pulp stem cells to be differentiated into the osteoblasts. According to osteoblast differentiation metaphase differentiation marker detection, the cell ALP activity of a group added with 800ng / mL of brucella outer membrane protein is 2.36 times that of a conventional osteoblast induction culture medium group; according to osteoblast differentiation end-stage differentiation marker detection, the calcium deposition amount of brucella outer membrane proteome cells added with 800ng / mL is 481.54 mu g / mg protein, and is 2.55 times of that of a conventional osteoblast induction culture medium group. By adding the brucella outer membrane protein into a conventional osteoblast induction culture medium, the osteogenic differentiation efficiency of the dental pulp stem cells can be effectively improved.

The invention discloses magnesium-containing mesoporous active bioglass with drug sustained release, immunoregulation and bone metabolism regulation effects and application thereof. The drug-loaded MBGN is prepared by doping Mg ions and loading drugs, and the drug-loaded MBGN has good biocompatibility and can be decomposed in an acid environment to achieve controllable slow release of the drugs; on the other hand, released ions such as Si, Ca and Mg have a certain immunoregulation function, polarization of macrophages from M1 type to M2 type is promoted, inflammatory response is reduced, differentiation and maturation of osteoclasts are inhibited, and meanwhile, the released ions and drugs carried in mesopores play a synergistic effect, so that a good treatment effect is achieved. The drug-loaded MBGN provided by the invention has various biological properties, can overcome the defects of low drug loading rate, insufficient anti-inflammatory effect and the like when the existing mesoporous bioactive glass material is applied clinically, and has a good application prospect.

The invention discloses an electroactive dressing used for promoting bone cell differentiation and bone regeneration and used for negative pressure therapy and a manufacturing method. The manufacturing method of the electroactive dressing comprises the steps that S1, a PLLA / BG spinning solution is prepared; s2, preparing a PLLA / BG nanofiber membrane through electrostatic spinning; s3, vacuum drying; s4, PAMAM-NH2 surface modification, the negative pressure treatment dressing relates to the technical field of negative pressure treatment dressings, when mechanical deformation is generated during negative pressure work, the piezoelectric biological film generates continuous electric stimulation, and the electric stimulation has positive and beneficial effects on osteoblasts and bone tissue physiological processes. The generated electric effect continuously collects functional electrolyte in surrounding tissues, and the functional electrolyte is separated in the wound by the dendrimer PAMAM-NH2, so that excessive exudation caused by negative pressure treatment is effectively made up. Meanwhile, the flow of the electrolyte further strengthens a local electric signal, so that cell migration and osteoblast proliferation and differentiation are effectively promoted.

The invention discloses combined lactobacillus salivarius CCFM1398 for regulating and controlling bone homeostasis and relieving bone resorption and a metagen of the combined lactobacillus salivarius CCFM1398, and belongs to the technical field of microorganisms. The combined lactobacillus salivarius CCFM1398 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that expression of protein level and gene level of MC3T3-E1 cell osteoprotegerin (OPG) is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors TNF-alpha, IL-6 and MPO of the orthodontic bone absorption rat is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The present invention relates to a nanomaterial for preventing tumor bone metastasis, a preparation method therefor, and use thereof. The present invention has discovered a spatiotemporal coupling interaction between tumor cells and osteoclasts, and provides a tumor-bone initial metastasis behavior-targeting strategy which can accurately prevent tumor metastasis on the basis of the source, and can avoid drug resistance and biochemical drug resistance. On this basis, the present invention designs a physical killing nanomaterial targeting tumor-osteoclast conjugates, the nanomaterial being a bone targeting group-modified nanovesicle encapsulating a carbonate compound and a phosphate compound. The nanomaterial can be effectively concentrated in bone tissue; when tumor cells are activated, the acid secretion function of tumor-related osteoclasts in nearby tumor-osteoclast conjugates which are in contact with the tumor cells triggers the carbonate compound to generate carbon dioxide gas and promotes the release of the phosphate compound, which forms calcium phosphate crystals with calcium ions so as to kill nearby tumor cells, thus achieving a specific very-early tumor metastasis inhibition effect.

The invention discloses a gelatin-hyaluronic acid injectable hydrogel drug-carrying nanoparticle composite material as well as a preparation method and application thereof, relates to the technical field of biomedicine, and solves the problems that in the prior art, existing drugs for treating cartilage related diseases are difficult to deliver; the chronic inflammatory response in the articular cavity cannot be effectively controlled and cartilage cells cannot be protected at the same time, so that the application effect of the medicine is limited. The preparation method disclosed by the invention comprises the following steps: S1, obtaining a carnosine modified hyaluronic acid derivative Car-HA; s2, preparing nano particles (FNPs) loaded with fenofibrate; and S3, mixing the gelatin solution containing the FNPs with a Car-HA solution, adding transglutaminase into the mixed system, and carrying out an enzymatic cross-linking reaction to form the hydrogel FNPs-GelHA with a stable network structure. The CarHA and FNPs synergistic hydrogel strategy provided by the invention has good structural adjustability and drug adaptability, is suitable for delivery of various anti-inflammatory, anti-oxidation and cartilage repair drugs, and can be widely applied to local precise treatment of cartilage related diseases.

The invention provides modified milk powder capable of promoting bone health as well as a preparation method and application of the modified milk powder. The total protein content of the modified milk powder is 17-35 g / 100 g, the fat content of the modified milk powder is 1-32 g / 100 g, and the calcium content of the modified milk powder is 0.8-2.1 g / 100 g. Moreover, the modified milk powder contains bovine coloctrum and lactoferrin, the mass ratio of the bovine coloctrum to the lactoferrin is (5-100): 1 on the basis of the dry matter content, and the content of the lactoferrin in the modified milk powder is 2-400 mg / 100 g. The bovine colostrum and the lactoferrin are combined for preparing the milk powder, have a synergistic effect on promoting osteoblasts and inhibiting osteoclast proliferation, and are beneficial to bone health.

The invention belongs to the technical field of biological medicines, and particularly discloses a collagen peptide composition for enhancing immunostimulation osteoblast synthesis and a preparation method thereof, the collagen peptide composition comprises the following components by mass: 0.05-0.2% of taurine, 0.1-1% of vitamin C, 5-20% of type II collagen peptide, 5-20% of type III collagen peptide, and the balance of bovine bone collagen peptide. On the basis of the bovine bone collagen peptide, under the action of the taurine, the vitamin C, the II type collagen peptide, the III type collagen peptide and the red date extract, immunity can be effectively improved, osteoblasts are stimulated to synthesize the collagen peptide, and therefore the bone mineral density is effectively increased, and the osteoporosis is reduced. Wherein the red date extract and the bovine bone collagen peptide have a remarkable synergistic effect.

The invention discloses a bifidobacterium animalis subsp. Lactis BA-C53 and an application of the bifidobacterium animalis subsp. Lactis BA-C53 in products for improving bone health. The bifidobacterium animalis subsp. Lactis BA-C53 is classified and named as bifidobacterium animalis subsp. Lactis Bifidobacterium animalis subsp. Lactis BA-C53, the preservation number is CCTCC NO: M 2024460, the preservation unit is China Center for Type Culture Collection, and the preservation time is March 11, 2024. The bifidobacterium animalis subsp. Lactis BA-C53 can effectively improve the steady state of intestinal flora of a mouse with osteoporosis induced by estrogen deficiency, so that the relative abundance of phylum firmicalis and phylum actinomycetes is increased, the relative abundance of phylum bacteroides is reduced, and then short-chain fatty acid is generated to activate intestinal immunity and maintain the integrity of an intestinal barrier, so that the osteoporosis caused by estrogen deficiency is inhibited. Meanwhile, osteoclast differentiation can be inhibited by regulating NFATC1, RANKL and OPG pathways, then osteoporosis is relieved, and the compound can be widely applied to preparation of food and drugs.

The present disclosure generally relates to compositions and methods for treating a disease or condition associated with insufficient opening of Cx43 hemichannels in osteocytes, preferably for treating cancer, cancer metastasis, osteosarcoma, osteoporosis, or osteopenia.

The invention provides a Falcarindiol derivative, preparation thereof and application of the Falcarindiol derivative in preparation of medicines for preventing and / or treating bone diseases. The structural general formula of the Falcarindiol derivative is as shown in formula I in the specification. Experimental results show that the Falcarindiol derivative can significantly inhibit osteoclast differentiation, and is expected to be used for preparing novel drugs for preventing and / or treating osteoporosis, osteoporosis fracture, osteolysis, periprosthetic osteolysis, tumor bone metastasis, inflammatory bone loss, periodontitis inflammatory bone resorption and other bone diseases. # imgabs0 #